Proteolytic inhibitors as alternative medicines to treat trypanosomatid-caused diseases: experience with calpain inhibitors
Open Access
- 1 January 2022
- journal article
- research article
- Published by FapUNIFESP (SciELO) in Memórias do Instituto Oswaldo Cruz
- Vol. 117, e220017
Abstract
The treatment for tropical neglected diseases, such as Chagas disease (CD) and leishmaniasis, is extremely limited to a handful of drugs that suffer from unacceptable toxicity, tough administration routes, like parenteral, and increasing treatment failures due to the parasite resistance. Consequently, there is urgency for the development of new therapeutic options to treat such diseases. Since peptidases from these parasites are responsible for crucial functions in their biology, these molecules have been explored as alternative targets. In this context, a myriad of proteolytic inhibitors has been developed against calcium-dependent cysteine-type peptidases, collectively called calpains, which are implicated in several human pathophysiological diseases. These molecules are highly expanded in the genome of trypanosomatids and they have been reported participating in several parasite biological processes. In the present perspective, we discuss our almost two decades of experience employing the calpain inhibitors as an interesting shortcut to a possible repurpose strategy to treat CD and leishmaniasis.Keywords
This publication has 27 references indexed in Scilit:
- Expression of calpain-like proteins and effects of calpain inhibitors on the growth rate of Angomonas deanei wild type and aposymbiotic strainsBMC Microbiology, 2015
- Drug repurposing and human parasitic protozoan diseasesInternational Journal for Parasitology: Drugs and Drug Resistance, 2014
- The Calpain Inhibitor MDL28170 Induces the Expression of Apoptotic Markers in Leishmania amazonensis PromastigotesPLOS ONE, 2014
- Strategies to Combat Antimicrobial ResistanceJournal of Clinical and Diagnostic Research, 2014
- How to Fight Back Against Antibiotic ResistanceAmerican Scientist, 2014
- Massive expansion of the calpain gene family in unicellular eukaryotesBMC Ecology and Evolution, 2012
- MDL28170, a Calpain Inhibitor, Affects Trypanosoma cruzi Metacyclogenesis, Ultrastructure and Attachment to Rhodnius prolixus MidgutPLOS ONE, 2011
- Hospital Epidemiology and Infection Control in Acute-Care SettingsClinical Microbiology Reviews, 2011
- Arrested growth ofTrypanosoma cruziby the calpain inhibitor MDL28170 and detection of calpain homologues in epimastigote formsParasitology, 2009
- Antileishmanial activity of MDL 28170, a potent calpain inhibitorInternational Journal of Antimicrobial Agents, 2006